Overview
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma.
NICE has also produced early value assessment guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
The information provided includes a description of the technology, how it’s used and its potential role in the treatment pathway. A MIB also includes a review of relevant published evidence and the likely costs of using the technologies, but it is not NICE guidance and does not make any recommendations on the value of using the technologies.